EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, ORIC: Oric Pharmaceuticals Inc

05 Nov 25 15:59
LAST:

12.37

CHANGE:
 0.08		OPEN:
12.10		HIGH:
12.54		ASK:
0.00		VOLUME:
602.8K
CHG(%):
0.65		PREV:
12.30		LOW:
11.88		BID:
0.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
05 Nov 2512.3612.5411.8812.38920.7K
04 Nov 2512.3012.7112.1612.301.73M
03 Nov 2513.0613.4212.2612.691.21M
31 Oct 2513.2413.5713.0313.161.17M
30 Oct 2512.7513.5112.7513.34908.5K
29 Oct 2513.4213.5712.9012.931.1M
28 Oct 2513.2113.8113.1213.43896.1K
27 Oct 2513.5513.6912.9513.401.27M
24 Oct 2512.5813.3812.4713.101.46M
23 Oct 2512.0612.4611.8812.42993.3K

COMPANY PROFILE

Name:Oric Pharmaceuticals Inc
About:ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. The company develops ORIC-533, an orally bioavailable small molecule inhibitor of CD73; and ORIC-613, a small molecule therapeutic intended to address a mechanism of innate resistance found in a subset of breast cancers. It has clinical development collaboration agreement for a potential Phase 2 study of ORIC-533 in multiple myeloma with Pfizer Inc.; a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Sector:Healthcare
Industry:Biotechnology
Address:240 East Grand Avenue, South San Francisco, CA, United States, 94080
Website:https://www.oricpharma.com
CUSIP:68622P109
CIK:0001796280
ISIN:US68622P1093
FIGI:BBG00BL5SLH5
LEI:54930033FJRNEYBW0L25

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-6.93 
Forward P/E:-6.48 
PEG Ratio:-1.56 
Price to Book:3.50 
Return on Assets:-0.28 
Return on Equity:-0.44 
EPS Ratio:-1.89 
Shares:97.12M 
Market Cap:1.201B 

TECHNICAL INDICATORS

MA5:12.773.3%
MA10:12.924.4%
MA20:13.055.5%
MA50:11.913.8%
MA100:11.1011.4%
MA200:9.1934.6%
STO9:5.30 
STO14:17.34 
RSI14:40.87
WPR14:-77.78
MTM14:-0.40
ROC14:-0.03 
ATR:0.73 
Week High:13.579.7%
Week Low:11.884.1%
Month High:14.9320.7%
Month Low:11.7134.6%
Year High:14.9320.7%
Year Low:3.90217.6%
Volatility:64.09